New Once-Daily Pill for Adults With HIV on Complex Treatment
Bixlenvo (bictegravir and lenacapavir) — a once-daily two-drug pill for adults with HIV who are already undetectable, including people on complex multi-tablet regimens
Medcelerator Brief
This is for adults living with HIV who are already undetectable on a stable regimen — including people taking several pills a day or complex multi-drug combinations — and who may be candidates for labelled US Bixlenvo as a once-daily switch. It explains the August 2026 FDA approval, the ARTISTRY Week 48 suppression numbers, the two-day Sunlenca start, Gilead Advancing Access, and how to talk with an HIV clinician — without treating this as a first-start drug, a failing-treatment rescue, a DIY import, or “approved” as funded. Authorized is not funded.
Bixlenvo (bictegravir and lenacapavir) is a once-daily oral complete regimen. On the US Prescribing Information (revised 08/2026) it is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO.
This is a traditional FDA approval (NDA 221104). It is not listed on FDA’s 2026 Novel Drug Approvals table because bictegravir and lenacapavir were already marketed in other products; the new labelled door is this fixed-dose combination for suppressed adults.
Distinct path — not this carton (fact-only): Idvynso (doravirine / islatravir) is a separate labelled tenofovir-free switch already covered elsewhere on Medcelerator. Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) is a three-drug STR — not this two-drug tablet. Sunlenca (lenacapavir) alone remains a separate product used here only for the two-day initiation load. Today’s US labelled once-daily bictegravir + lenacapavir complete-regimen switch for suppressed adults is Gilead Bixlenvo (NDA 221104).
The FDA approved NDA 221104 effective 27 August 2026. Applicant attention on the letter: April Raj, MS, Gilead Sciences, Inc., Foster City, CA. Letter signed Prabha Viswanathan, Division of Antivirals. Package Insert Reference ID 5859873. Manufactured for and distributed by Gilead Sciences, Inc., Foster City, CA 94404. Document code on patient labeling: 221104-GS-000.
Where this is taking place
Commercial labelled door today: United States — FDA-labelled Bixlenvo for adults with HIV-1 who are already suppressed on a stable regimen, prescribed through an HIV / infectious-disease clinic (or another clinician managing HIV), with a two-day oral Sunlenca initiation then daily Bixlenvo maintenance. Company patient materials describe Gilead Advancing Access® for cost-support navigation and point to www.BIXLENVO.com. This is a prescription HIV antiretroviral conversation — not a cure, not PrEP, and not a DIY import.
Outside the United States: As of this draft, no confirmed Health Canada Notice of Compliance, European Commission marketing authorisation, MHRA licence, TGA listing, Swissmedic authorisation, or PMDA/MHLW licence for Bixlenvo. Gilead’s August 2026 approval materials state bictegravir and lenacapavir in combination are not approved by any regulatory authority outside of the United States. Do not import on your own.
ARTISTRY-1 — NCT05502341 (GS-US-621-6289) — Randomized, open-label, multicenter Phase 3 switch from a complex stable baseline regimen to Bixlenvo vs staying on baseline. Lead sponsor: Gilead Sciences. CT.gov status at draft time: ACTIVE, NOT RECRUITING. Actual enrolment 689. USPI safety/efficacy N=557 randomized who received study drug framing in section 14 (Bixlenvo 371 / stay 186). Expanded access on this record: CT.gov reports hasExpandedAccess: false.
ARTISTRY-2 — NCT06333808 (GS-US-621-6290) — Randomized, double-blind Phase 3 switch from Biktarvy to Bixlenvo vs staying on Biktarvy. Lead sponsor: Gilead Sciences. CT.gov status: ACTIVE, NOT RECRUITING. Actual enrolment 577. USPI N=574 (Bixlenvo 383 / Biktarvy 191). hasExpandedAccess: false.
Honesty: Week 48 primary analyses support the label — that is not open new enrolment into the pivotal cohorts, and it is not the same sentence as “any pharmacy will have Bixlenvo tomorrow without an HIV clinician.”
The practical commercial door in the US is an HIV clinician who can confirm suppression, review resistance history (no known/suspected BIC or LEN resistance), plan the two-day Sunlenca + Bixlenvo initiation, check drug interactions (including dofetilide and strong CYP3A inducers), and arrange Advancing Access / payer logistics if needed.
Approval matrix
| Regulator | Status | Date | Notes |
|---|---|---|---|
| FDA (United States) | Approved NDA 221104. Traditional. | 27 Aug 2026 | Adults; suppressed switch; complete regimen. ARTISTRY Week 48 RNA <50 96% / 93%. NDC 61958-3601-1. |
| Health Canada | Not confirmed | — | No DIN / NOC asserted for Bixlenvo in this draft. |
| EMA / European Commission | Not confirmed | — | Company: combo not approved outside US. |
| MHRA (UK) | Not confirmed | — | — |
| TGA (Australia) | Not confirmed | — | — |
| PMDA / MHLW (Japan) | Not confirmed | — | — |
| Swissmedic | Not confirmed | — | — |
| Other | Not confirmed | — | — |
Access by country
-
United States: Ask an HIV / infectious-disease clinician about FDA-labelled Bixlenvo. Labelled 27 August 2026 as a complete regimen to replace current ART in adults already suppressed (RNA <50) on a stable regimen with no known or suspected resistance to bictegravir or lenacapavir. Path: confirm eligibility → Days 1 and 2: one Bixlenvo 75/50 mg tablet plus Sunlenca 600 mg (two 300 mg tablets) each day → Day 3 onward: one Bixlenvo tablet once daily → with or without food. If more than 7 days elapse since the last maintenance dose, restart the initiation regimen from Day 1 when continuing treatment is still clinically appropriate. Do not take Day 1 and Day 2 Sunlenca doses on the same day if a day was missed. Bottle: NDC 61958-3601-1 (30 tablets). Suspected adverse reactions: Gilead 1-800-GILEAD-5 or FDA MedWatch 1-800-FDA-1088. Patient information: 1-800-445-3235 or www.BIXLENVO.com. Cost-support navigation: Gilead Advancing Access® — 1-800-226-2056 (Mon–Fri 9 AM–8 PM ET on company materials) or gileadadvancingaccess.com. No list price or copay dollars in this article. This is US labelled commercial supply, not a DIY import.
-
Canada: Bixlenvo authorisation not confirmed. Ask the Canadian HIV clinic what legal paths exist in Canada when a Canadian Bixlenvo label does not yet exist.
-
European Union / United Kingdom / Australia / Japan / other countries: Regulator authorisation not confirmed in this draft. US trial sites are not a commercial foreign carton. Do not import on your own.
-
If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting — without treating a US bottle as a foreign carton.
Who is eligible (from the US label)
This is an adult switch for people already undetectable on the Prescribing Information — not a first-start regimen and not a labelled rescue for people whose current ART is failing.
United States (USPI, revised August 2026):
- Indication: Complete regimen to replace current ART in adults with HIV-1 who are virologically suppressed (RNA <50 copies/mL) on a stable regimen with no known or suspected resistance to bictegravir or lenacapavir.
- Recommended dosage: Two-day initiation (Bixlenvo + oral Sunlenca 600 mg daily) then Bixlenvo once daily; with or without food.
- Contraindications: Concomitant dofetilide; strong CYP3A inducers.
- Warnings: Risk of adverse reactions or loss of virologic response from drug interactions — review full interaction table before and during therapy.
- Most common adverse reactions (≥2%, all grades, ARTISTRY): headache (4% ARTISTRY-1), nausea (3%), diarrhea (2%).
- Other ART: Because Bixlenvo is a complete regimen, coadministration with other antiretrovirals for HIV-1 treatment is not recommended.
- Pregnancy / lactation: Lower bictegravir exposures observed with a BIC-containing regimen in pregnancy — monitor viral load closely; Antiretroviral Pregnancy Registry 1-800-258-4263. Individuals with HIV-1 should be informed of potential risks of breastfeeding.
- Pediatrics: Safety and effectiveness not established.
- HBV co-infection: Chronic HBV was excluded from ARTISTRY; discuss HBV status with the clinician (section 8.8 on USPI).
ARTISTRY trial context (USPI): Both trials required suppression for ≥6 months before entry. ARTISTRY-1 complex baseline: mean 3.5 oral pills/day (range 2–11); 71% on INSTI + PI–containing regimens among those described. ARTISTRY-1 mean age 59 (range 22–84); ARTISTRY-2 mean age 49 (range 23–77).
Not labelled on sources confirmed for this draft:
- Adults starting ART for the first time (treatment-naïve).
- People with known/suspected resistance to bictegravir or lenacapavir, or whose current regimen is failing.
- Children and adolescents.
- Canadian, EU, UK, Japanese, Australian, or Swiss Bixlenvo marketing authorisations (not confirmed here).
- Treating NCT05502341 / NCT06333808 follow-up as open commercial enrolment.
What the pivotal studies showed (Prescribing Information)
Use the Prescribing Information for a prescription conversation. Journals are supportive reading.
ARTISTRY-1 and ARTISTRY-2 — Week 48 virologic outcomes (USPI Table 11):
| Outcome | ARTISTRY-1 Bixlenvo (N=371) | ARTISTRY-1 stay (N=186) | ARTISTRY-2 Bixlenvo (N=383) | ARTISTRY-2 Biktarvy (N=191) |
|---|---|---|---|---|
| HIV-1 RNA ≥50 copies/mL | 1% | 1% | 1% | 1% |
| Treatment difference (95.002% CI) | −0.3% (−2.3% to 1.8%) | — | 0.3% (−1.9% to 2.4%) | — |
| HIV-1 RNA <50 copies/mL | 96% | 94% | 93% | 91% |
Trial-status honesty: Both CT.gov records ACTIVE, NOT RECRUITING at draft time. Labelled commercial switch ≠ open pivotal enrolment.
How it is taken (US label — keep this exact)
| Item | On-label detail |
|---|---|
| Drug | Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg) tablets |
| Day 1 | Bixlenvo 1 tablet and Sunlenca 600 mg (2 × 300 mg) |
| Day 2 | Bixlenvo 1 tablet and Sunlenca 600 mg (2 × 300 mg) |
| Day 3 and thereafter | Bixlenvo 1 tablet once daily |
| Food | With or without food |
| Missed maintenance >7 days | Restart initiation from Day 1 if continuing is clinically appropriate |
| Supply | Bottle of 30; NDC 61958-3601-1; store 20–25 °C; keep desiccant; original container |
Who / research team (primary sources only)
- Sponsor / applicant: Gilead Sciences, Inc., Foster City, CA (NDA letter; USPI).
- Letter attention: April Raj, MS, Associate Director, Regulatory Affairs (NDA 221104 approval letter).
- Pivotal trials: ARTISTRY-1 (NCT05502341); ARTISTRY-2 (NCT06333808) — lead sponsor Gilead Sciences on CT.gov.
- Patient support (company): Gilead Advancing Access® — 1-800-226-2056 / gileadadvancingaccess.com on company cost-support materials; product info 1-800-445-3235 / www.BIXLENVO.com on USPI patient labeling.
- Names and phones below are limited to what appears on the Prescribing Information, FDA approval letter, ClinicalTrials.gov, and clearly labelled company support materials.
Sources
- FDA — NDA 221104 Approval Letter for Bixlenvo (bictegravir and lenacapavir) tablets (27 Aug 2026; Reference ID 5859873).
- FDA / Gilead — Bixlenvo Prescribing Information (revised 08/2026).
- Gilead Sciences — U.S. FDA Approves Gilead’s Bixlenvo… press release (27 Aug 2026).
- ClinicalTrials.gov — NCT05502341 (ARTISTRY-1); NCT06333808 (ARTISTRY-2).
- Company patient materials — www.BIXLENVO.com / Cost Support / Advancing Access (1-800-226-2056).
Not medical advice. Talk with a clinician who knows the full history before any treatment decision. Authorized is not funded.
Who is behind this
- Sponsor
Primary on this piece
Gilead Sciences, Inc.
NDA 221104 applicant; USPI manufactured for / distributed by; ARTISTRY sponsor — Bixlenvo FDC (not Idvynso / Biktarvy / Sunlenca-alone)
MoreLess
FDA NDA 221104 applicant and USPI manufactured-for / distributed-by line for Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg) tablets. Foster City, CA. Traditional FDA approval 27 August 2026 as a once-daily complete regimen to replace current antiretroviral therapy in adults with HIV-1 who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable regimen with no known or suspected resistance to bictegravir or lenacapavir. Labelled course: Days 1–2 one Bixlenvo tablet plus oral Sunlenca (lenacapavir) 600 mg, then one Bixlenvo tablet once daily. Lead sponsor of ARTISTRY-1 (NCT05502341) and ARTISTRY-2 (NCT06333808). This fixed-dose combination is a distinct labelled product — not Idvynso (doravirine / islatravir), not Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide), and not Sunlenca-alone (lenacapavir alone).
Access / labelling
- Other
FDA CDER — Bixlenvo press/letter
Piece-scoped FDA NDA 221104 letter / Drugs@FDA / USPI path for Bixlenvo FDC (agency)
MoreLess
Piece-scoped US FDA CDER context for the 27 August 2026 traditional NDA 221104 approval of Bixlenvo (bictegravir and lenacapavir) tablets — approval letter and labelled USPI / Drugs@FDA path for the once-daily complete-regimen switch in suppressed adults. Division of Antivirals. Agency framing — not Gilead company personnel. This labelled door is the bictegravir / lenacapavir fixed-dose combination, not Idvynso, not Biktarvy, and not Sunlenca-alone.
Trials
- Other
ARTISTRY-1 / ARTISTRY-2 investigators
ARTISTRY-1 (NCT05502341) / ARTISTRY-2 (NCT06333808) programme investigators
MoreLess
Programme-level investigator context for ARTISTRY-1 (NCT05502341; complex-regimen switch) and ARTISTRY-2 (NCT06333808; Biktarvy switch) — the two Phase 3 trials supporting the US Bixlenvo label. ClinicalTrials.gov actual enrolment 689 and 577; USPI efficacy N=557 and N=574. Status ACTIVE, NOT RECRUITING on both records — follow-up is not a new commercial enrolment door and not open recruitment for a new pivotal cohort. Week 48 HIV-1 RNA less than 50 copies per mL: 96% versus 94% (ARTISTRY-1) and 93% versus 91% (ARTISTRY-2). No personal principal investigator is named here from ClinicalTrials.gov.
Other organizations
- Other
Gilead Advancing Access
Company cost-support navigation (not the label)
MoreLess
Company cost-support navigation programme for labelled US Bixlenvo (bictegravir / lenacapavir), described on Gilead patient-support materials — not the Prescribing Information itself. Helps eligible patients navigate insurance and assistance under an HIV-clinician prescription. Not a treating clinic directory, not a retail pickup, and not a foreign marketing authorisation.
People
April Raj, MS
Gilead Associate Director, Regulatory Affairs — NDA 221104 approval letter addressee
MoreLess
Associate Director, Regulatory Affairs, Gilead Sciences, Inc. Addressee on the FDA NDA 221104 Bixlenvo (bictegravir and lenacapavir) approval letter dated 27 August 2026. Company regulatory contact named on the letter — not a ClinicalTrials.gov site investigator and not labelled here as a CT.gov PRINCIPAL_INVESTIGATOR.